TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01339039
Drug: Plerixafor
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given subcutaneously once daily; MTD determined in Part 1 will be used as dose in Part 3.
Study: NCT01339039
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given intravenously on days 1 and 15 (10 mg/kg) of each 28-day cycle
Study: NCT01339039
Drug: Plerixafor
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily administration for 5-9 days prior to surgery
Study: NCT00905996
Drug: Beta-blocker (propranolol)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00214266
Drug: Campath 1H®, Rituximab, mycophenolate mofetil
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction therapy with Campath 30mg IV x 2 doses, Rituximab 375mg/m2 x 1, corticosteroids, and mycophenolate 1000mg bid
Study: NCT04302402
Drug: Rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin has been demonstrated in multiple IBS studies, through a postulated effect on the gut microbiota, to improve the symptoms of pain and bloating, which are important symptoms in subjects with functional dyspepsia
Study: NCT02432339
Drug: mycophenolate mofetil (MMF)
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: an immunosuppressant - 500 mgs twice a day for 7 1/2 days - in capsule form
Study: NCT00257972
Drug: aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03921736
Drug: Perindopril
Normalized name: Perindopril
DrugBank: Perindopril (DB00790)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 mg/day p.o. for 12 months
Study: NCT03921736
Drug: Hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hydrochlorothiazide 25 mg/day p.o. for 12 months
Study: NCT03921736
Drug: Estracomb TTS
Normalized name: TT 173
DrugBank: TT 173 (DB17717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal patches releasing 17β-estradiol (0.05 mg/24 hours) and norethisterone (0.25 mg/24 hours) for 12 months
Study: NCT01805037
Drug: brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00803062
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00803062
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00803062
Drug: Topotecan Hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02274740
Drug: LIXISENATIDE AVE0010
DrugBank: Lixisenatide (DB09265)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study: NCT02274740
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT03048877
Drug: Apatinib Oral Tablet
Normalized name: lapatinib Oral Tablet
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apatinib Mesylate Tablets
Study: NCT02898454
Drug: Mometasone furoate nasal spray
Normalized name: mometasone furoate Nasal Spray
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Suspension~Route of administration: Intranasal
Study: NCT02718911
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered IV
Study: NCT02718911
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT05237726
Drug: Enoxaparin 40 mg q24 hours
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severely burn injuries (BSA≥20%) will be assigned to 3 modality regimens of pharmacological VTE prophylaxis: Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours.
Study: NCT05237726
Drug: Enoxaparin 30 mg q12 hours
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severely burn injuries (BSA≥20%) will be assigned to 3 modality regimens of pharmacological VTE prophylaxis: Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours.
Study: NCT01982695
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00080665
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel (15-30 mg/m2, IV, weekly on days 1, 8, and 15) each 28 day cycle
Study: NCT00080665
Drug: imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate (400-600 mg, oral, once daily) each 28 day cycle
Study: NCT01982695
Drug: Lisinopril
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03781466
Drug: vaginal progesterone
Normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily vaginal progesterone 400mg from diagnosis of short cervix to 36 weeks
Study: NCT00672568
Drug: 4975 - Highly purified capsaicin
Normalized name: Purified oxgall
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution, 0.5 mg, single dose, injection
Study: NCT00672568
Drug: 4975 - Highly purified capsaicin
Normalized name: Purified oxgall
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution, 0.75 mg, single dose, injection
Study: NCT00672568
Drug: 4975 - Highly purified capsaicin
Normalized name: Purified oxgall
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution, 0.1 mg, Single dose, injection
Study: NCT02212119
Drug: Botulinum Toxin
Normalized name: Botulinum toxin
DrugBank: Botulinum toxin type B (DB00042)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02212119
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01076543
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT01906788
Drug: Artemether Lumefantrine 6 dose regimen & single dose of Primaquine on day 0
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01906788
Drug: Artemether Lumefantrine 6 dose regimen and single dose Primaquine on day 2
Normalized name: artemether and lumefantrine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01076543
Drug: Temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT00026091
Drug: fenretinide
Normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT01056393
Drug: ibalizumab 800mg Q2Weeks
Normalized name: ibalizumab
DrugBank: Ibalizumab (DB12698)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ibalizumab is a humanized IgG4 monoclonal antibody and is provided as a parenteral formulation at a concentration of 25mg/mL in a 10mL glass vial, 8mLs per vial, as the investigational product. Study drug will be administered via intravenous infusion at doses of 800mg every 2 weeks.
Study: NCT01056393
Drug: ibalizumab 2000mg Q4Weeks
Normalized name: ibalizumab
DrugBank: Ibalizumab (DB12698)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ibalizumab is a humanized IgG4 monoclonal antibody and is provided as a parenteral formulation at a concentration of 25mg/mL in a 10mL glass vial, 8mLs per vial, as the investigational product. Study drug will be administered via intravenous infusion at doses of 2000mg every 4 weeks.
Study: NCT04414852
Drug: Apatinib Mesylate
Normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All the subjects will be administrated with 250mg apatinib on day 1
Study: NCT01435759
Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg
Normalized name: lisdexamfetamine dimesylate 10 MG
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Antidepressant + SPD489 oral, 10 mg, once daily for 8 weeks
Study: NCT01435759
Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg
Normalized name: lisdexamfetamine dimesylate 30 MG
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Antidepressant + SPD489 oral, 30 mg, once daily for 8 weeks
Study: NCT01435759
Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg
Normalized name: lisdexamfetamine dimesylate 50 MG
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Antidepressant + SPD489 oral, 50 mg, once daily for 8 weeks
Study: NCT01435759
Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg
Normalized name: lisdexamfetamine dimesylate 70 MG
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Antidepressant + SPD489 oral, 70 mg, once daily for 8 weeks
Study: NCT02689804
Drug: LNG-EC
Normalized name: EC-0652
DrugBank: EC-0652 (DB15340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDA-approved emergency contraceptive pill containing levonorgestrel 1.5mg
Study: NCT02689804
Drug: UPA-EC
Normalized name: EC-0652
DrugBank: EC-0652 (DB15340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDA-approved emergency contraceptive pill containing ulipristal acetate 30mg
Study: NCT01820897
Drug: Fosfomycin-Trometamol
Normalized name: trometamol
DrugBank: Fosfomycin (DB00828)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01820897
Drug: Sulfamethoxazole trimethoprim
Normalized name: sulfamethoxazole / trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00116961
Drug: Velcade
Normalized name: Velcade
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00116961
Drug: Doxil
Normalized name: Doxil
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00116961
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01071681
Drug: Telmisartan (Kinzal/Pritor, BAY68-9291)
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients under daily life treatment receiving Pritor according to local drug information.
Study: NCT01691690
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam (0.5mg/kg to maximum dose of 20mg) given 15-20 minutes before induction.
Study: NCT01691690
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane for anesthesia induction.
Study: NCT01691690
Drug: Nitrous Oxide/Oxygen
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination of NO2 \& O2 for anesthesia induction.
Study: NCT01701804
Drug: Chuna herbal medicine
Normalized name: China-Gel
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120ml of Chuna herbal medicine(Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, and Cuscuta chinensis) taken twice a day 30 minutes after meals for 16 weeks
Study: NCT01691690
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 1-1.5 mg/kg to facilitate endotracheal intubation.
Study: NCT01691690
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine 0.1 mg/kg given prior to intubation.
Study: NCT02998255
Drug: Split dose of 4L PEG
Normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients at average risk for inadequate BP were given instructions for bowel preparation through phone call a day before scheduled colonoscopy. the participants began to drink the first 2 L of PEG at 7:00-9:00 PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients took the remaining 2 L 4-6 hours before colonoscopy.
Study: NCT01691690
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron (0.15 mg/kg, maximum dose of 4 mg) for postoperative nausea prophylaxis.
Study: NCT01691690
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (0.25 mg/kg, maximum dose of 20 mg) for postoperative nausea prophylaxis.
Study: NCT04062760
Drug: Early sequential nephron blockade
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After 24-72 hours of an algorithm-based treatment with high-dose intravenous furosemide started at the time of hospital admission, the patients in this arm will be randomized to receiving:~1. oral furosemide in 2 daily divided doses at a dose equivalent to that administered intravenously during the past 24 hours~2. metolazone at a dose based on serum creatinine value~3. acetazolamide at a dose based on serum creatinine value~4. spironolactone or potassium canrenoate (unless serum potassium value is higher than 5 mmol/L); dose will be established based on serum creatinine value
Study: NCT00436072
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infusion once weekly
Study: NCT00436072
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Infusion once the safe dose of ZD6474 and cetuximab is established
Study: NCT04362943
Drug: Baricitinib or Anakinra
Normalized name: anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment with either Baricitinib or Anakinra during hospitalization, in real world, and under usual clinical care.
Study: NCT02143323
Drug: Augmentin tablet
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02225132
Drug: Hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The precise mechanism by which hydroxyurea produces its cytotoxic and cytoreductive effects is not known. However, various studies support the hypothesis that hydroxyurea causes an immediate inhibition of DNA synthesis by acting as a ribonucleotide reductase inhibitor, without interfering with the synthesis of ribonucleic acid or of protein.~The mechanisms by which DROXIA produces its beneficial effects in patients with sickle cell anemia (SCA) are uncertain. Known pharmacologic effects of DROXIA that may contribute to its beneficial effects include increasing hemoglobin F levels in RBCs, decreasing neutrophils, increasing the water content of RBCs, increasing deformability of sickled cells, and altering the adhesion of RBCs to endothelium.
Study: NCT01302080
Drug: sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non interventional study - drug, dose, duration etc as per USPI and clinician discretion
Study: NCT00214578
Drug: Seroquel (quetiapine)
Normalized name: quetiapine Oral Tablet [Seroquel]
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02392520
Drug: cetrorelix (cetrotide)
Normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25 mg GnRH antagonist cetrorelix will be administered once daily for 4 days, starting on the day of severe early OHSS diagnosis
Study: NCT03729375
Drug: 10cc injection of bupivacaine
Normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10cc intra-operative injection of bupivacaine into the carpal tunnel of the operative hand/wrist
Study: NCT03729375
Drug: 20cc injection of bupivacaine
Normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20cc intra-operative injection of bupivacaine into the carpal tunnel of the operative hand/wrist
Study: NCT03702855
Drug: Tetrabenazine Tablets 25 mg
Normalized name: Tetrabenazine
DrugBank: Tetrabenazine (DB04844)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00946023
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days -6 through -2: 30 mg/m\^2 IV daily
Study: NCT00946023
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Start on Day 5 through Day 180
Study: NCT00225238
Drug: esomeprazole (PPI)
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03282669
Drug: Intrathecal Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal Morphine administered in the operating room.
Study: NCT03282669
Drug: Intravenous hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous hydromorphone administered via IV in the post operative area.
Study: NCT02144792
Drug: [11C] -verapamil PET
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: While P-gp inhibitor (Cyclosporin A, 2.5mg/kg/hr during 2hours, intravenous) is infused, PET scans were done using \[11C\] -verapamil, a substrate of P-gp.
Study: NCT03425097
Drug: Fexofenadine
Normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine 180 mg in the morning
Study: NCT01793753
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04256980
Drug: Pemigatinib
Normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pemigatinib will be self-administered at 9mg Or 13.5mg as a QD oral treatment on a 2-week-on therapy and 1-week-off therapy schedule
Study: NCT00145769
Drug: Concurrent Chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5FU 225mg/m2/day delivered IV over continous 7 day period for the duration of radiotherapy (5 1/2 weeks).
Study: NCT02768532
Drug: Vedolizumab
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: During each 8 visits (screening, V0, V1, V2, V3, V4, V5, V6) at weeks-1, 0, 2, 6, 10, 14, 22, 54, respectively), the following parameters will be systematically recorded: Crohn's disease Activity Index (CDAI), adverse events.~Blood and fecal samples will be systematically collected at weeks 0, 2, 6, 10, 14, 22 and 54 for routine serum ultrasensitive CRP (C-Reactive Protein) and fecal calprotectin assessments and for vedolizumab pharmacokinetic parameters, including the vedolizumab trough levels and the specific anti-Vedolizumab antibodies. In case of loss of response, an additional measurement of serum CRP (C-Reactive Protein), fecal calprotectin and Vedolizumab pharmacologic parameters will be performed.
Study: NCT00689390
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In previous treatment studies, ribavirin was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
Study: NCT00024141
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02324010
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100mg mane for 2 days
Study: NCT00667056
Drug: tacrolimus ointment
Normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topical
Study: NCT03402802
Drug: monitoring of adherence with medication
Normalized name: salicylic acid Medicated Patch [Compound W brand of salicylic acid]
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: persons taking routine postoperative eye drops will have their frequency of drop taking monitored
Study: NCT00697021
Drug: Aspirin (200mg) and/or Plavix (150mg) dosage according to TEG
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non- responders to Aspirin or Plavix shown on TEG analysis will be treated by doubling of Aspirin (200mg) and/or Plavix (150mg) dosage
Study: NCT01983371
Drug: Ferumoxytol
Normalized name: Ferumoxytol
DrugBank: Ferumoxytol (DB06215)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All study patients will receive a dose of ferumoxytol for the MRI. Ferumoxytol will be administered intravenously at a dose of 6 mg/kg, for a maximum dose of 510 mg.
Study: NCT04210505
Drug: Povidone-Iodine Topical Ointment
Normalized name: povidone-iodine Topical Ointment
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal povidone-iodine will be applied to the lower anterior nares (i.e. nostril) of patients undergoing hemodialysis before each session.
Study: NCT02928224
Drug: Encorafenib
Normalized name: encorafenib
DrugBank: Encorafenib (DB11718)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Orally, once daily.
Study: NCT02928224
Drug: Binimetinib
Normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Orally, twice daily.
Study: NCT02928224
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard of care.
Study: NCT02928224
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard of care.
Study: NCT02928224
Drug: Folinic Acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard of care.
Study: NCT02928224
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard of care.
Study: NCT00000338
Drug: Lisuride
Normalized name: lisuride
DrugBank: Lisuride (DB00589)
Approvals — FDA: no, EMA: no, PMDA: no